Rezubio Secures $20 Million Series A to Advance Novel Membrane-Anchored Drug Platform for Obesity and Diabetes
Key Insights
Rezubio (search), founded by former Merck (search) scientists, closed a $20 million Series A financing led by Lapam Capital (search) to advance its membrane-anchored drug design platform.
The company's lead gut-targeted GPCR (search) agonist for obesity and diabetes has entered clinical trials in Australia, with Phase 2 development planned.
Rezubio (search)'s MADD platform uses engineered kinetophores to anchor drugs to target tissues, enabling localized pharmacology while minimizing systemic exposure.
Rezubio (search), a China-based biotechnology company founded by former Merck (search) scientists, announced the closing of a $20 million Series A financing round to advance its innovative membrane-anchored therapeutics platform. The funding, led by Lapam Capital (search) with participation from Frees Fund (search) and Riverhead Capital (search), will support the company's lead program into Phase 2 clinical development for obesity and diabetes, along with other programs in IND-enabling and early preclinical stages.
Breakthrough Platform Technology
The company's proprietary Membrane-Anchored Drug Design (MADD) platform represents a novel approach to tissue-selective drug delivery. The technology uses a rationally engineered kinetophore to anchor pharmacophores to the epithelium of target tissues, enabling localized drug activity at the site of action.
"Membrane anchoring has the potential to reshape how targeted medicines are designed," said Yusheng Xiong, PhD, co-founder and CEO of Rezubio (search). "Our MADD platform enables highly localized pharmacology for cell-surface targets, including GPCRs, while minimizing systemic exposure."
The MADD platform is designed to address key limitations of conventional therapeutics by delivering minimal systemic exposure to reduce off-target and dose-limiting adverse effects, enhanced efficacy through enrichment of active compounds around cell-surface target proteins, and prolonged tissue residence time to support less frequent dosing.
Clinical Pipeline Progress
Rezubio (search)'s gut-targeted GPCR (search) agonist has entered clinical trials in Australia and is expected to provide critical proof-of-concept for the platform technology. The company plans to advance this lead program into Phase 2 clinical development for obesity and diabetes using proceeds from the Series A financing.
In parallel development, an antagonist targeting a different GPCR (search) for immune and inflammatory diseases is scheduled to enter Phase 1 clinical development in early 2026, expanding the platform's therapeutic applications beyond metabolic disorders.
Addressing Therapeutic Limitations
By targeting limitations of conventional small-molecule and peptide therapeutics—including adverse effects and frequent administration requirements—Rezubio (search) aims to improve both therapeutic index and patient compliance. The membrane-anchored approach offers the potential to enhance drug efficacy while reducing systemic side effects that often limit treatment options.
"This Series A represents an important inflection point for Rezubio (search)," Xiong noted, highlighting the company's transition from platform development to clinical validation across multiple therapeutic areas.